Axogen
Yahoo Finance • 17 days ago
AxoGen Conference: AVANCE BLA Approval, Debt Paydown Fuel 2026 Growth Target of 18%+
AxoGen logo AxoGen (NASDAQ:AXGN) executives outlined a year of accelerating commercial momentum, recent balance sheet improvements, and the operational implications of its December Biologics License Application (BLA) approval for AVANCE d... Full story
Yahoo Finance • last month
AxoGen Q4 Earnings Call Highlights
AxoGen logo AxoGen (NASDAQ:AXGN) reported fourth-quarter and full-year 2025 results that management said marked a “financial inflection point,” citing accelerating adoption of the company’s nerve repair algorithm, improved operating lever... Full story
Yahoo Finance • last month
HighMark Wealth Management Buys 158,855 Shares of Axogen Stock
In its fourth-quarter 13F filing, HighMark Wealth Management LLC disclosed a purchase of 158,855 shares in Axogen(NASDAQ:AXGN) . This purchase makes the stock one of the firm’s largest holdings. What happened According to its Feb. 4, 202... Full story
Yahoo Finance • last month
Axogen (AXGN) Benefited from Multiple Tailwinds
Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S. equity markets navigated a quarter supported by optimis... Full story
Yahoo Finance • last month
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced tha... Full story
Yahoo Finance • 4 months ago
Axogen gets FDA OK for Avance’s biologics license application
[Mature female virologist examining test tube while working in laboratory] Maskot * Axogen (AXGN [https://seekingalpha.com/symbol/AXGN]) on Wednesday said [https://seekingalpha.com/pr/20328257-axogen-announces-fda-approval-of-biologics-... Full story
Yahoo Finance • 4 months ago
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, today announced... Full story
Yahoo Finance • 5 months ago
Axogen, Inc. Reports Third Quarter 2025 Financial Results
ALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported fina... Full story
Yahoo Finance • 5 months ago
Here are the major earnings before the open Wednesday
Major earnings expected before the bell on Wednesday include: * Verizon Communications (VZ [https://seekingalpha.com/symbol/VZ]) * The Boeing Company (BA [https://seekingalpha.com/symbol/BA]) * Caterpillar (CAT [https://seekingalpha... Full story
Yahoo Finance • 6 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. (“Axogen” or the “Company”) (NASDAQ: AXGN). Such investors are advised to contact Danielle Peyton at newaction@po... Full story
Yahoo Finance • 7 months ago
Stocks Settle Lower as Bond Yields Rise
The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) on Monday closed down by -0.43%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.... Full story
Yahoo Finance • 7 months ago
Stocks Turn Mixed on Strength in the Magnificent Seven Megacaps
The S&P 500 Index ($SPX) (SPY) today is down by -0.15%, the Dow Jones Industrials Index ($DOWI) (DIA) is down by -0.49%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up by +0.03%. September E-mini S&P futures (ESU25) are down -0.13%, and Sep... Full story
Yahoo Finance • 7 months ago
Axogen stock falls after FDA extends review timeline for nerve graft
Investing.com -- Axogen (NASDAQ:AXGN) stock declined 9% after the U.S. Food and Drug Administration (FDA) extended its review timeline for the company’s Avance Nerve Graft by three months. The FDA has pushed the Prescription Drug User Fee... Full story
Yahoo Finance • 7 months ago
Stocks Pressured by Rising Bond Yields
The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is down by -0.15%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futu... Full story
Yahoo Finance • 7 months ago
Axogen falls 16% after FDA delays Avance Nerve Graft decision to December
Axogen (NASDAQ:AXGN [https://seekingalpha.com/symbol/AXGN]) shares fell 16% in premarket trading after [https://seekingalpha.com/pr/20209800-axogen-provides-update-on-fda-review-timeline-for-avance-nerve-graft] the company announced that t... Full story
Yahoo Finance • 7 months ago
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
ALACHUA, Fla. and TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biolo... Full story
Yahoo Finance • 7 months ago
Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Small Cap Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, equity markets experienced a significant re... Full story
Yahoo Finance • 7 months ago
Raymond James Slashes PT on Axogen (AXGN) to $20 From $21
Axogen, Inc. (NASDAQ:AXGN) is one of the best medical device stocks to buy according to analysts. On August 6, Raymond James analyst Jayson Bedford lowered the firm’s price target on Axogen, Inc. (NASDAQ:AXGN) to $20 from $21, keeping an O... Full story
Yahoo Finance • 8 months ago
Axogen Inc (NASDAQ:AXGN) Surges 15.8% After Q2 2025 Earnings Beat and Raised Guidance
AXOGEN INC (NASDAQ:AXGN [https://www.chartmill.com/stock/quote/AXGN]) BEATS Q2 2025 ESTIMATES, RAISES FULL-YEAR GUIDANCE Axogen Inc reported its second-quarter 2025 financial results, delivering revenue and earnings per share (EPS) that e... Full story
Yahoo Finance • 8 months ago
These stocks are moving in today's pre-market session
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. [premarket] GAINERS TICKER CHANGE COMMENT AIP [https://www.chartmill.com/stock/quote/AIP/... Full story
